首页> 外文OA文献 >The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

【2h】

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

机译：Brentuximab Vedotin（Adcetris）的欧洲药物局审查用于治疗成人复发或难治性CD30 + Hodgkin淋巴瘤或全身厌备大细胞淋巴瘤的综述：用于人类使用的药品委员会科学评估摘要

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Iordanis Gravanis; Kyriaki Tzogani; Paula Hennik; Pieter Graeff; Petra Schmitt; Jan Mueller‐Berghaus; Tomas Salmonson; Christian Gisselbrecht; Edward Laane; Lothar Bergmann; Francesco Pignatti;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use [J] . Iordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, The oncologist . 2016,第1期

机译：欧洲药物管理局对布伦妥昔单抗Vedotin（Adcetris）进行的治疗成年复发或难治性CD30 +霍奇金淋巴瘤或系统间变性大细胞淋巴瘤的成年患者的综述：人类用药品委员会的科学评估摘要
2. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Product for Human Use [J] . Gravanis Iordanis, Tzogani Kyriaki, van Hennik Paula, The oncologist . 2016,第1期

机译：欧洲药物管理局对布伦妥昔单抗Vedotin（Adcetris）进行的治疗成年复发或难治性CD30 +霍奇金淋巴瘤或系统间变性大细胞淋巴瘤的成年患者的综述：人类用药品委员会的科学评估摘要
3. The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use [J] . Elias P??an, Beatriz Flores, Ian Hudson, The oncologist . 2013,第5期

机译：欧洲药品管理局对匹克酮的治疗，用于治疗成年复发性或难治性侵袭性非霍奇金氏B细胞淋巴瘤成年患者：人类用药品委员会的科学评估摘要
4. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use [O] . Iordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, 2016

机译：欧洲药物管理局对布伦妥昔单抗Vedotin（Adcetris）的治疗用于治疗成年复发或难治性CD30 +霍奇金淋巴瘤或系统间变性大细胞淋巴瘤的成人患者：人类用药品委员会的科学评估摘要
5. The European Medicines Agency Review of Ofatumumab (Arzerra®) for the Treatment of Chronic Lymphocytic Leukemia in Patients Refractory to Fludarabine and Alemtuzumab: Summary of the Scientific Assessment of the European Medicines Agency Committee for Medicinal Products for Human Use [O] . Gravanis, Iordanis, Ersbøll, Jens, Skovlund, Eva, 2010

机译：欧洲药物管理局对Ofatumumab（Arzerra®）的氟达拉滨和Alemtuzumab难治性患者治疗慢性淋巴细胞性白血病的评论：欧洲药物管理局人类使用药品的委员会的科学评估摘要

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

著录项

相似文献

相关主题

期刊订阅